ORIC - Oric Pharmaceuticals, Inc.

9.65
-0.540   -5.596%

Share volume: 1,621,105
Last Updated: 04-28-2026
Pharmaceutical Products/Pharmaceutical Preparations: -0.12%

PREVIOUS CLOSE
CHG
CHG%
$10.19
-0.54
-0.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
41%
Profitability 35%
Dept financing 19%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-5.76%
1 Month
-20.84%
3 Months
-10.32%
6 Months
-25.37%
1 Year
70.65%
2 Year
17.25%
Key data
Stock price
$9.65
P/E Ratio 
0.00
DAY RANGE
$9.46 - $10.46
EPS 
-$1.52
52 WEEK RANGE
$4.52 - $14.93
52 WEEK CHANGE
$69.00
MARKET CAP 
796.644 M
YIELD 
N/A
SHARES OUTSTANDING 
100.358 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-05-2025
BETA 
1.99
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,344,789
AVERAGE 30 VOLUME 
$2,527,147
Company detail
CEO: Jacob M. Chacko
Region: US
Website: oricpharma.com
Employees: 80
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

ORIC Pharmaceuticals, Inc. discovers and develops therapies for treatment of cancers. Its product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Recent news